Heart Failure

Featured Article

The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview

The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview

To examine the link between cardiovascular disease and sleep apnea, The Cardiology Advisor spoke with cardiologist Seth S. Martin, MD, MHS, FACC, FAHA and sleep specialist Rachel Marie E. Salas, MD, FAAN.

Latest Features

The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview

The Connection Between Cardiovascular Disease and Sleep Apnea: An Expert Interview

To examine the link between cardiovascular disease and sleep apnea, The Cardiology Advisor spoke with cardiologist Seth S. Martin, MD, MHS, FACC, FAHA and sleep specialist Rachel Marie E. Salas, MD, FAAN.

Managing Heart Failure: Improving Quality of Life and Preventing Excerbations

Managing Heart Failure: Improving Quality of Life and Preventing Excerbations

Heart failure is the number 1 reason for patient re-admittance to acute-care facilities according to the American Heart Association.

Preventing Heart Failure One Risk Factor at a Time

Preventing Heart Failure One Risk Factor at a Time

Avoiding 3 major risk factors for heart failure—hypertension, diabetes, and obesity—may reduce the likelihood of heart failure development.

Hope for Heart Failure in Thyroid Hormone Therapy

Hope for Heart Failure in Thyroid Hormone Therapy

Subclinicial hypothyroidism has been associated with an increased risk for coronary heart disease events and mortality.

Premature Ventricle Contractions in Heart Failure: A Closer Examination

Premature Ventricle Contractions in Heart Failure: A Closer Examination

A primer on premature ventricle contractions with commentary from 2 arrhythmic/heart failure experts.

ARVD/Cardiomyopathy: Interview with Expert Hugh Calkins, MD

ARVD/Cardiomyopathy: Interview with Expert Hugh Calkins, MD

While ARVD/C management has greatly improved, more precautions—particularly in genetic testing and exercise—need to be taken.

Clinician Viewpoints on the "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure"

Clinician Viewpoints on the "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure"

Drs Tauras and Patel from Montefiore Medical Center in the Bronx, New York weigh in on what the new heart failure therapeutic guidelines mean for practicing clinicians.

Managing Cardiovascular Complications of Oncology Treatment

Managing Cardiovascular Complications of Oncology Treatment

Clinicians seek stronger collaboration between cardiology and oncology as well as evidence-based treatment guidelines.

Ixmyelocel-T Cell-Based Therapy Reduced Cardiac Events in Heart Failure

Ixmyelocel-T Cell-Based Therapy Reduced Cardiac Events in Heart Failure

Ixmyelocel-T therapy reduced clinical cardiac events and improved patient outcomes.

Better Late Than Never: Exercise as Primary and Secondary Prevention in CVD

Better Late Than Never: Exercise as Primary and Secondary Prevention in CVD

Exercise's potential positive effects on cardiovascular disease and heart failure may be possible regardless of frequency and time of initiation.

Latest News

LVAD in Heart Failure Linked to Improved Glycemic Control

LVAD in Heart Failure Linked to Improved Glycemic Control

HbA1c levels following left ventricular assist device implantation were statistically significantly lower than before surgery.

FDA Fast Track Designation Granted to Praliciguat for HFpEF

FDA Fast Track Designation Granted to Praliciguat for HFpEF

The Company is currently enrolling patients in a randomized, double-blind, placebo-controlled Phase 2 trial; they expect to enroll 175 in total.

Outcomes With Rivaroxaban in Chronic Heart Failure With Underlying CAD

Outcomes With Rivaroxaban in Chronic Heart Failure With Underlying CAD

Rivaroxaban was not superior to placebo for reducing the rate of death, MI, or stroke in patients with chronic heart failure.

Tafamidis Reduces Mortality, Hospitalizations in Transthyretin Amyloid Cardiomyopathy

Tafamidis Reduces Mortality, Hospitalizations in Transthyretin Amyloid Cardiomyopathy

Tafamidis was associated with reduced all-cause mortality and cardiovascular-related complications in patients with transthyretin amyloid cardiomyopathy.

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

Reducing HF Hospitalization Risk: Antidiabetic Drug Classes Compared

The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.

Evaluating Excess Risk for Heart Failure Hospitalization in Type 2 Diabetes

Evaluating Excess Risk for Heart Failure Hospitalization in Type 2 Diabetes

Investigators examined the excess risk for heart failure in patients with type 2 diabetes and compared the risk with that in the general population without diabetes.

Labeling Mix-Up Prompts Recall of HCTZ Bottles That May Contain Another Diuretic

Labeling Mix-Up Prompts Recall of HCTZ Bottles That May Contain Another Diuretic

To date, there have been no reports of any adverse events related to this recall.

Emphysema Associated With Worse Outcomes in Heart Failure

Emphysema Associated With Worse Outcomes in Heart Failure

After 2.1 years of follow-up, 49% of patients who had emphysema on chest CT were readmitted for heart failure and 24% had died.

Entresto Initiation Soon After Acute HF Episode Safe in HFrEF Patients

Entresto Initiation Soon After Acute HF Episode Safe in HFrEF Patients

The Phase 4, randomized, open-label, parallel-group TRANSITION study (N=1002) evaluated the safety and tolerability of Entresto in HFrEF patients after they were stabilized following an acute heart failure episode when treatment was initiated either pre-discharge or post-discharge.

New Clinical Trial Targets Gut Microbiota in Heart Failure

New Clinical Trial Targets Gut Microbiota in Heart Failure

GutHeart, a new ongoing clinical trial, will investigate the potential benefits of treating gut bacteria in heart failure.

Sign Up for Free e-Newsletters